On February 23, 2021 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021 (Press release, Spectrum Pharmaceuticals, FEB 23, 2021, View Source [SID1234575473]). The oral presentation will provide some initial safety and efficacy data for poziotinib from the twice daily dosing cohort. The meeting takes place on March 1 – 2, 2021. Details of the presentations are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma
Speaker: Sribalaji Lakshmikanthan, Ph.D.
Session: Immunotherapy (ID 361)
Date and Time: March 1, 2021, 9:41 a.m. CET / 3:41 a.m. ET
Presentation Number: #20P (poster)

Title: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
Speaker: Adrian Sacher, M.D.
Session: Mini Oral Session (ID 17) Channel 1
Date and Time: March 2, 2021, 17:25 CET / 11:25 a.m. ET
Presentation Number: 36MO (mini-oral)

Access to the presentations is available to members of ESMO (Free ESMO Whitepaper) and can be found here: View Source;module=attendee#signin